Erivedge receives conditional EU approval

Roche announce that the European Commission has granted conditional approval to Erivedge.

Erivedge is a once a day tablet for adult patients with advanced basal cell carcinoma (BCC), i.e. metastatic BCC which has spread to other parts of the body or locally advanced BCC which has invaded surrounding tissue and is considered inappropriate for surgery or radiotherapy.   

On 15/07/2013 Hal Barron MD, Roche's Chief Medical Officer and Head of Global Product Development stated "Today's approval is great news for patients with advanced basal cell carcinoma, who previously had no medicines to treat their disease. Erivedge substantially reduced tumour size in patients in clinical trials, and we are pleased that Erivedge will now be available to patients in the European Union."

This new treatment will be good news for individuals affected by Gorlin syndrome with advanced BCC.  Further information is available here.

 Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello.  We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support. 
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361 
Gorlin Syndrome community on HealthUnlocked
website security